回盛生物(300871.SZ)：报告期内取得了7个宠物产品批文，极大扩展了宠物产品线

Group 1 - The core focus of the company is on the pet pharmaceutical sector, which is considered a key development direction [1] - The company has adjusted resource allocation to increase investment in pet pharmaceutical research and market channel development [1] - The company has established an independent and specialized research team for pet pharmaceuticals and has obtained approval for 7 pet products during the reporting period, significantly expanding its product line [1] Group 2 - The company's pet pharmaceutical products mainly cover various segments, including antiparasitics, analgesics, dermatological medications, internal medicine, and functional health products [1]